Why Monsanto raises important issues for biotech industry
It will remain difficult to get protection for recombinant products purely on the basis of a patent to the gene, following the Court of Justice’s recent decision in the Monsanto case – according to the UK’s BioIndustry Association
In a statement on the decision, which is the first time the EU’s Court of Justice has interpreted an issue of substantive patent law, John Murphy, chair of the BIA’s IP Advisory Committee said the ruling raises "some important issues...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.